Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

Autor:	Keiser, Philip H.1 Philip.Keiser@utsouthwestern.edu, Sension, Michael G.2 msension@nbhd.org, De Jesus, Edwin3 EdwinDeJesusMD@aol.com, Rodriguez, Allan4 arodriguez2@med.miami.edu, Olliffe, Jeffrey F.5 jolliffe@u.washington.edu, Williams, Vanessa C.6 vanessa.c.williams@gsk.com, Wakeford, John H.6 john.h.wakeford@gsk.com, Snidow, Jerry W.6 jerry.w.snidow@gsk.com, Shachoy-Clark, Anne D.6 anne.d.shachoy-clark@gsk.com, Fleming, Julie W.6 julie.w.fleming@gsk.com, Pakes, Gary E.6 gary.e.pakes@gsk.com, Hernandez, Jaime E.6 jaime.e.hernandez@gsk.com
Zdroj:	BMC Infectious Diseases. 2005, Vol. 5 Issue 1, p2-15. 15p. 2 Charts, 6 Graphs.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu